ILMN

Illumina Inc. develops and markets integrated systems for DNA sequencing, genotyping, and gene‑expression analysis, selling sequencing instruments that generate recurring revenue from proprietary consumables, reagents, flow cells and associated software services. The company operates in the biotechnology and life‑science tools sector, focusing on next‑generation sequencing (NGS) technologies that enable large‑scale genomic research and clinical diagnostics. It is widely recognized as the dominant global provider of short‑read NGS platforms, with its NovaSeq, NextSeq and MiSeq systems forming the standard infrastructure for academic, pharmaceutical and healthcare laboratories worldwide.